MCID: PST011
MIFTS: 52

Pustulosis of Palm and Sole

Categories: Skin diseases

Aliases & Classifications for Pustulosis of Palm and Sole

MalaCards integrated aliases for Pustulosis of Palm and Sole:

Name: Pustulosis of Palm and Sole 12 15
Psoriasis 43 71
Pustular Psoriasis of the Palms and/or Soles 12
Acrodermatitis Continua of Hallopeau 71
Generalized Pustular Psoriasis 71
Pustulosis of Palms and Soles 71
Palmoplantar Pustulosis 12
Acropustulosis 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4398
MeSH 43 D011565
NCIt 49 C34888
SNOMED-CT 67 27520001
ICD10 32 L40.3
UMLS 71 C0030246 C0033860 C0343055 more

Summaries for Pustulosis of Palm and Sole

MalaCards based summary : Pustulosis of Palm and Sole, also known as psoriasis, is related to psoriasis 14, pustular and pustular psoriasis, and has symptoms including pruritus, exanthema and psoriasiform rash. An important gene associated with Pustulosis of Palm and Sole is CCR6 (C-C Motif Chemokine Receptor 6), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Esomeprazole and Dapsone have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and testes, and related phenotypes are hematopoietic system and homeostasis/metabolism

Related Diseases for Pustulosis of Palm and Sole

Diseases related to Pustulosis of Palm and Sole via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1432)
# Related Disease Score Top Affiliating Genes
1 psoriasis 14, pustular 33.2 IL36RN AP1S3
2 pustular psoriasis 33.1 TNF IL36RN AP1S3
3 impetigo herpetiformis 32.9 IL36RN IL1RL2 CARD14 AP1S3
4 pustulosis palmaris et plantaris 32.7 TNF IL36RN CCR6 AP1S3
5 geographic tongue 32.5 LPIN2 IL36RN IL1RL2 CARD14
6 systemic onset juvenile idiopathic arthritis 32.3 TNF IL1RN
7 metal allergy 30.7 TNF IL17A
8 necrobiosis lipoidica 30.6 TNFRSF1B TNF
9 nail disease 30.5 TNFRSF1B TNF IL17A CCR6
10 crohn's colitis 30.4 TNF CXCL8 CCR6
11 lichen planus 30.4 TNF IL17A CXCL8
12 spondyloarthropathy 30.4 TNF IL17A CCR6
13 cutaneous candidiasis 30.4 IL17A CCR6
14 acrodermatitis 30.3 TNFRSF1B IL36RN IL1RL2 CARD14 AP1S3
15 skin sarcoidosis 30.3 TNFRSF1B TNF
16 granuloma annulare 30.3 TNFRSF1B TNF
17 acute generalized exanthematous pustulosis 30.2 IL36RN IL17A CXCL8
18 guillain-barre syndrome 30.2 TNFRSF1B TNF CCR6
19 allergic contact dermatitis 30.2 TNF IL17A CXCL8
20 childhood type dermatomyositis 30.1 TNFRSF1B TNF CCR6
21 arthropathy 30.1 TNF IL1RN CRP
22 herpes zoster 30.1 TNFRSF1B TNF CRP CCR6
23 osteomyelitis 30.0 TNF LPIN2 IL1RN CXCL8
24 posterior uveitis 29.9 TNF MRAP CCR6
25 dermatitis 29.9 TNF IL17A CXCL8 CCR6
26 leprosy 3 29.9 TNF IL17A CXCL8 CCR6
27 dermatitis, atopic 29.9 TNF IL17A CXCL8 CCR6
28 alopecia areata 29.9 TNF IL1RN IL17A
29 chickenpox 29.9 TNFRSF1B TNF CRP CCR6
30 keratitis, hereditary 29.8 TNF IL17A CCR6
31 stomatitis 29.8 TNF IL1RN CXCL8
32 colitis 29.8 TNF IL17A CXCL8 CCR6
33 mumps 29.8 TNFRSF1B TNF CXCL8
34 enthesopathy 29.7 TNFRSF1B TNF MRAP CRP CCR6
35 contact dermatitis 29.7 TNF IL17A CXCL8
36 acquired immunodeficiency syndrome 29.7 TNFRSF1B TNF CRP CCR6
37 balanitis 29.7 MRAP CRP
38 dermatitis herpetiformis 29.7 TNF IL17A CXCL8
39 sleep apnea 29.7 TNF CXCL8 CRP
40 parasitic helminthiasis infectious disease 29.7 TNF SIGLEC5 IL17A CCR6
41 histoplasmosis 29.7 TNFRSF1B TNF IL17A CCR6
42 psoriasis 29.7 TNFRSF1B TNF IL36RN IL17A CXCL8 CCR6
43 vaginitis 29.7 TNF CXCL8 CCR6
44 birdshot chorioretinopathy 29.7 MRAP IL17A CCR6
45 candidiasis 29.6 TNF IL17A CXCL8 CCR6
46 streptococcal toxic-shock syndrome 29.6 TNF CXCL8
47 macular retinal edema 29.6 TNF MRAP CXCL8
48 peptic ulcer disease 29.6 TNF IL1RN CXCL8
49 bacterial conjunctivitis 29.6 SIGLEC5 CXCL8 CRP
50 rosacea 29.6 TNF CXCL8 CRP CCR6

Graphical network of the top 20 diseases related to Pustulosis of Palm and Sole:



Diseases related to Pustulosis of Palm and Sole

Symptoms & Phenotypes for Pustulosis of Palm and Sole

UMLS symptoms related to Pustulosis of Palm and Sole:


pruritus, exanthema, psoriasiform rash

MGI Mouse Phenotypes related to Pustulosis of Palm and Sole:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.96 CCR6 IL17A IL1RL2 IL1RN IL36RN LPIN2
2 homeostasis/metabolism MP:0005376 9.9 CCR6 CRP IL17A IL1RL2 IL1RN IL36RN
3 immune system MP:0005387 9.73 CARD14 CCR6 CRP IL17A IL1RL2 IL1RN
4 integument MP:0010771 9.23 CARD14 IL17A IL1RL2 IL1RN IL36RN PSTPIP2

Drugs & Therapeutics for Pustulosis of Palm and Sole

Drugs for Pustulosis of Palm and Sole (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 440)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7, 161973-10-0 9568614 4594
2
Dapsone Approved, Investigational Phase 4 80-08-0 2955
3
Desoximetasone Approved Phase 4 382-67-2 5311067
4
Clobetasol Approved, Experimental, Investigational Phase 4 25122-41-2, 25122-46-7 32798 5311051
5
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
6
Clocortolone Approved Phase 4 4828-27-7, 34097-16-0 5282493 5311052
7
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
8
Sodium citrate Approved, Investigational Phase 4 68-04-2
9
Mannitol Approved, Investigational Phase 4 69-65-8 6251 453
10
carbamide peroxide Approved Phase 4 124-43-6
11 Strawberry Approved Phase 4
12 Orange Approved Phase 4
13 Artichoke Approved Phase 4
14
Sorafenib Approved, Investigational Phase 4 284461-73-0 216239 406563
15
Abatacept Approved Phase 4 332348-12-6 10237
16
Zinc Approved, Investigational Phase 4 7440-66-6 32051
17
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
18 Ixekizumab Approved, Investigational Phase 4 1143503-69-8
19 Brodalumab Approved, Investigational Phase 4 1174395-19-7
20
Ustekinumab Approved, Investigational Phase 4 815610-63-0
21
Metformin Approved Phase 4 657-24-9 14219 4091
22 Vedolizumab Approved Phase 4 943609-66-3
23
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
24
Sotalol Approved Phase 4 3930-20-9, 959-24-0 5253
25
Adalimumab Approved Phase 4 331731-18-1 16219006
26
Certolizumab pegol Approved Phase 4 428863-50-7
27
Tofacitinib Approved, Investigational Phase 4 477600-75-2
28
Mercaptopurine Approved Phase 4 50-44-2 667490
29
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
30
Salicylic acid Approved, Investigational, Vet_approved Phase 4 69-72-7 338
31
Capsaicin Approved Phase 4 404-86-4 1548943
32
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
33
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
34
Glycine Approved, Nutraceutical, Vet_approved Phase 4 56-40-6 750
35
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 5280453 134070
36 retinol Phase 4
37 Retinol palmitate Phase 4
38 Tin Fluorides Phase 4
39 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
40 Immunoglobulin A Phase 4
41 Halobetasol Phase 4
42
Chondroitin Phase 4 9007-27-6 53477707
43 Clocortolone pivalate Phase 4
44 Olive Phase 4
45 Omega 3 Fatty Acid Phase 4
46 Chelating Agents Phase 4
47 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
48 Citrate Phase 4
49 diuretics Phase 4
50 Anticoagulants Phase 4

Interventional clinical trials:

(show top 50) (show all 1686)
# Name Status NCT ID Phase Drugs
1 Improvement in the Quality of Life of Patients With Severe Plaque Psoriasis Treated With Systemic Methotrexate in Fixed Doses of 10mg or 25mg Orally Once Weekly: a Prospective, Randomized, Double-blind, Parallel Group Study. Unknown status NCT02248792 Phase 4 Methotrexate
2 A Phase4,Multicenter, Randomized,Double-blind,Double Dummy, Parallel Controlled Study Evaluating the Efficacy and Safety of Triptergium Wilfordii and Acitretin in Treatment of Chinese Patients With Moderate to Severe Psoriasis Vulgaris Unknown status NCT01443338 Phase 4 Triptergium Wilfordii;Acitretin
3 A Phase 4 Multicenter, Randomized, Placebo-controlled Study Evaluating the Effect of Apremilast on Pruritus and Quality of Life of Patients With Moderate-to-severe Scalp Psoriasis Unknown status NCT03553433 Phase 4 Apremilast 30mg;Placebo Oral Tablet
4 The Difference of Circulating Endothelial-derived and Platelet-derived Microparticles in Patients With Psoriasis Successfully Treated With Stelara(Ustekinumab) Unknown status NCT02693470 Phase 4 Ustekinumab
5 Proton Pump Inhibitors Use in Patients With Psoriasis Unknown status NCT02624544 Phase 4 esomeprazole;desonide
6 Phase IV Study on Efficacy and Safety of the Combination Treatment Acitretin and Efalizumab in Moderate to Severe Chronic Plaque Psoriasis Unknown status NCT00707070 Phase 4 efalizumab plus placebo;efalizumab plus acitretin
7 An Open Label Trial to Show That Subjects With Severe Plaque-Type Psoriasis Receiving Acitretin 25 mg/Day And Stabilized On A Photochemotherapy Regimen Who Are Experiencing Retinoid-Related Adverse Events, Benefit From A Reduction In Acitretin Dose to 17.5 mg/Day, While Maintaining Comparable Efficacy Along With Improved Tolerability Unknown status NCT01228409 Phase 4 Acitretin 17.5 mg/day
8 Efficacy of Combined Fractional Carbon Dioxide Laser and Topical Tazarotene in the Treatment of Psoriatic: Nail Disease a Single-blind, Intrapatient Left-to-right Controlled Study. Unknown status NCT03263624 Phase 4 Tazarotene Cream 0.1%
9 An Open-label Study to Evaluate the Efficacy of Re-treatment for Patients With a History of Etanercept Use Unknown status NCT01132235 Phase 4
10 The Influence of Adalimumab vs. Fumaric Acid Esters on Cardiovascular and Metabolic Risk Factors in the Therapy of Patients With Moderate to Severe Psoriasis Vulgaris Unknown status NCT01088165 Phase 4 Adalimumab treatment arm;Fumaric acid esters treatment group
11 Weight Reduction Alone May Not be Sufficient to Maintain Disease Remission in Obese Patients With Psoriasis: a Randomized, Investigator-blinded Study Unknown status NCT01439425 Phase 4
12 Evaluation of Lymphocytic Infiltrate, Dendritic Cells and Cytokines Expression in Psoriatic Lesion and Normal Skin Before and After Adalimumab Therapy Unknown status NCT01237262 Phase 4 Adalimumab, etanercept, infliximab
13 A Double - Blind, Placebo Controlled Crossover Study to Evaluate The Efficacy and Tolerability of Stelara ™ (Ustekinumab) in The Treatment of Scalp Psoriasis Unknown status NCT01558310 Phase 4 Ustekinumab;Placebo
14 Home UVB Phototherapy for Psoriasis: Effectiveness, Quality of Life and Cost-Effectiveness Unknown status NCT00150930 Phase 4
15 A Randomized Controlled Trial Comparing the Efficacy and Safety Profile of Oral Versus Subcutaneous Route of Methotrexate Administration in Moderate to Severe Psoriasis Unknown status NCT03408756 Phase 4 methotrexate
16 Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Comparison With Tuberculin Skin Test in Patients With Psoriasis and Psoriatic Arthritis Unknown status NCT01223976 Phase 4
17 A Phase IV, Randomised, Multicentre, Double-blind, Study to Evaluate the Clinical Utility of Prospective Genetic Screening (HLA-B*1301) for Susceptibility to Dapsone Hypersensitivity Syndrome Unknown status NCT02550080 Phase 4 Dapsone
18 The Effect of Vitamin A Supplementation on CD4+ T-cell Secretion in Obese Individuals Unknown status NCT01405352 Phase 4
19 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Etanercept in Treating Scalp Involvement in Subjects With Moderate to Severe Plaque Psoriasis Completed NCT00791765 Phase 4
20 Canadian Assessment of Patient Outcomes and Effectiveness of Enbrel (Etanercept) in Psoriasis Completed NCT00332332 Phase 4
21 A Randomized, Open Label Study to Evaluate the Safety and Efficacy of Etanercept in the Treatment of Subjects With Psoriasis Completed NCT00195507 Phase 4 Etanercept
22 A Randomized, Double-Blind Trial Assessing the Efficacy and Safety of Etanercept 50 mg Twice Weekly and Etanercept 50 mg Once Weekly for the Treatment of Moderate to Severe Psoriasis Completed NCT00663052 Phase 4 Etanercept;Etanercept
23 Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex® (Clobetasol Propionate) Spray 0.05% Completed NCT01893567 Phase 4 Clobex Spray
24 A Multicenter, Open-label, Randomized, Pilot-study to Evaluate the Efficacy and Safety of the Combination of Etanercept (ETN) and Methotrexate and of Etanercept (ETN) Alone in Patients With Plaque Psoriasis Despite Methotrexate Therapy Completed NCT00161655 Phase 4 Etanercept;Methotrexate
25 A Randomized Pilot Study Evaluating the Efficacy and Safety of Etanercept in Patients With Moderate to Severe Plaque Psoriasis After Cessation of Ciclosporin Therapy Completed NCT00581555 Phase 4 Etanercept
26 Optimizing Psoriasis Treatment of Etanercept Combined Methotrexate: a Phase IV, Multicenter, Randomized, Double-blind, Controlled Trial Completed NCT02313922 Phase 4 etanercept combined with methotrexate or etanercept combined with placebo
27 An Open-Label Phase 4 Study in Adult Patients With Chronic Plaque Psoriasis to Evaluate the Immune Response to Pneumococcal Vaccine in Subjects Treated With Alefacept Completed NCT00493324 Phase 4 alefacept;polyvalent pneumococcal vaccine
28 An Extension Study of Brodalumab in Subjects With Plaque Psoriasis (Psoriasis Vulgaris, Psoriatic Arthritis), Pustular Psoriasis (Generalized) and Psoriatic Erythroderma Completed NCT04183881 Phase 4 Brodalumab 210mg SC
29 Elocon vs Fluticasone in Localized Psoriasis Completed NCT00763529 Phase 4 Mometasone;Fluticasone
30 Evaluating Safety in Patients With Moderate to Severe Psoriasis Treated With Etanercept Completed NCT00581165 Phase 4 Etanercept
31 A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis Completed NCT03573323 Phase 4 Ixekizumab;Guselkumab;Placebo
32 Long-term Treatment of Scalp Psoriasis With Xamiol® Gel in a Large Adult Chinese Population Completed NCT02533973 Phase 4 Xamiol® gel;Daivonex® scalp solution
33 Fase IV Clinical Trial to Evaluate Chondroitin Sulphate Efficacy and Safety in Patients With Knee Osteoarthritis and Psoriasis Completed NCT00669123 Phase 4 Chondroitin sulphate;Placebo
34 Safety and Efficacy of Etanercept in Patients With Moderate to Severe Plaque Psoriasis Who Have Shown an Unsatisfactory Response to Adalimumab or Infliximab Completed NCT00967538 Phase 4 etanercept 50 mg
35 A Trial That Compound Clobetasol Propionate Ointment Treats Patients With Mild to Moderate Psoriasis Vulgaris. Completed NCT02733874 Phase 4 Compound Clobetasol Propionate Ointment;Calcipotriol Betamethasone Ointment
36 A Randomised, Double-Blind, Active-Controlled, Parallel, Multi-Center Study to Investigate the Efficacy and Safety of Daivobet® Ointment in Patients With Psoriasis Vulgaris Completed NCT00248456 Phase 4 Calcipotriol plus betamethasone dipropionate ointment
37 An Open-Label, Multicenter Study of the Efficacy of Cloderm® Cream (Clocortolone Pivalate, 0.1%) in the Treatment of Moderate Plaque Psoriasis for 28 Days Completed NCT01714544 Phase 4 Cloderm Cream
38 A Multicentre, Open Label Phase IIIb/IV Study of Subcutaneously Administered Raptiva in the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Completed NCT00287118 Phase 4 Efalizumab
39 Efficacy and Safety of Alefacept in Combination With Narrow-band UVB (nbUVB) Compared to Alefacept Alone in Subjects With Moderate to Severe Chronic Plaque Psoriasis Completed NCT00658606 Phase 4 alefacept
40 An Open-Label, Study Evaluating Topicort® Topical Spray 0.25% (Desoximetasone) in Patients With Scalp Psoriasis Completed NCT02985736 Phase 4 Topicort Topical Spray
41 A Study to Evaluate the Efficacy and Tolerability of Clobetasol Propionate vs. Vehicle in the Treatment of Mild to Moderate Plaque-Type Psoriasis Completed NCT00842153 Phase 4 Clobetasol propionate foam;Vehicle foam
42 An Open Label, Non-comparative, Multicentre, Phase IV Study to Evaluate the Safety, Tolerability and Efficacy of Tinefcon in Patients With Plaque Psoriasis Completed NCT01373567 Phase 4 TINEFCON
43 A Single-Center, Open-Label Study to Assess Change in Psychosocial and Occupational Dimensions With Ustekinumab Treatment of Moderate-to-Severe Psoriasis Evaluated With the Psychological General Well Being (PGWB), Work Productivity and Activity Impairment (WPAI), Psoriasis Quality of Life-12 Items (PQOL-12), and Dermatology Life Quality Index (DLQI) Completed NCT01511315 Phase 4 Ustekinumab
44 A Study to Evaluate Safety and Efficacy of Clobetasol Propionate for Treatment of Plaque-Type Psoriasis in Adult Subjects. Completed NCT00852761 Phase 4 Olux-E Foam;Clobex lotion
45 Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed Therapy With Apremilast Completed NCT02749370 Phase 4 Etanercept
46 A Multicenter, Open-Label, Pilot Trial to Evaluate the Effectiveness and Safety of ENBREL(r) in Combination With Narrowband UVB Phototherapy for the Treatment of Psoriasis Completed NCT00110981 Phase 4 Etanerept;Etanercept
47 A PHASE IV, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFECTS OF USTEKINUMAB ON VASCULAR INFLAMMATION IN PSORIASIS Completed NCT02187172 Phase 4 Ustekinumab;Placebo
48 A Single-arm Study to Assess the Immunogenicity and Safety of Etanercept Produced Using a Modified Process in Subjects With Plaque Psoriasis Completed NCT02274792 Phase 4 Etanercept
49 An Evaluation of the Efficacy, Safety, Preference and Duration of Response of Clobex® (Clobetasol Propionate) Spray and Taclonex® (Calcipotriene 0.05%/Betamethasone Dipropionate 0.064%) Ointment in Subjects With Stable Plaque Psoriasis Completed NCT00437255 Phase 4 Clobetasol Propionate, 0.05%;Calcipotriene and betamethasone dipropionate ointment
50 A Comparison Between Clobetasol Propionate (Clobex®) Spray and Clobetasol Propionate (Olux®) Foam With Regard to Efficacy, Safety, Preference and Duration of Response in Stable Plaque Psoriasis Completed NCT00436540 Phase 4 Clobetasol Propionate 0.05% Spray;Clobetasol Propionate 0.05% Foam

Search NIH Clinical Center for Pustulosis of Palm and Sole

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Acitretin
alefacept
Aloe vera preparation
Anthralin
ANTHRALIN PWDR
Betamethasone
Betamethasone acetate
Betamethasone benzoate
betamethasone dipropionate
betamethasone sodium phosphate
Betamethasone valerate
BETAMETHASONE VALERATE PWDR
calcipotriene
Calcitriol
Cholecalciferol
Coal Tar
Coal tar extract
Coal tar pitch volatiles
COAL TAR,COLLOIDAL
COAL TAR,REFINED
Cod Liver Oil
Colloid sulfur
Cyclosporine
Etretinate
Fish Liver Oils
fluocinolone
Fluocinolone Acetonide
hydroxyurea
Methotrexate
Methotrexate Sodium
Methoxsalen
mycophenolate mofetil
mycophenolate mofetil hydrochloride
Salicylic Acid
SALICYLIC ACID PWDR
Sulfur
SULFUR PWDR
SULFUR,COLLOIDAL
tazarotene
Thioguanine
Trioxsalen

Cochrane evidence based reviews: psoriasis

Genetic Tests for Pustulosis of Palm and Sole

Anatomical Context for Pustulosis of Palm and Sole

MalaCards organs/tissues related to Pustulosis of Palm and Sole:

40
Skin, T Cells, Testes, Liver, Neutrophil, Endothelial, Bone

Publications for Pustulosis of Palm and Sole

Articles related to Pustulosis of Palm and Sole:

(show top 50) (show all 30000)
# Title Authors PMID Year
1
Tackling the various classes of nano-therapeutics employed in topical therapy of psoriasis. 61
32393082 2020
2
Etanercept biosimilar (recombinant human tumor necrosis factor-α receptor II: IgG Fc fusion protein) and methotrexate combination therapy in Chinese patients with moderate-to-severe plaque psoriasis: a multicentre, randomized, double-blind, placebo-controlled trial. 61
31873772 2020
3
Psoriasin and rs4819554 of IL-17RA gene polymorphism in psoriasis. 61
32157372 2020
4
PGAxBSA composite versus PASI: Comparison across disease severities and as therapeutic response measure for Cal/BD foam in plaque psoriasis. 61
32430142 2020
5
Efficacy of combined liman peloid baths and heliotherapy in the treatment of psoriasis at Cervia spa, Emilia, Italy. 61
32133542 2020
6
Non-invasive delivery of biological macromolecular drugs into the skin by iontophoresis and its application to psoriasis treatment. 61
32360305 2020
7
Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry. 61
32213306 2020
8
Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study. 61
32032692 2020
9
Decoding active components in a formulation of multiple herbs for treatment of psoriasis based on three cell lines fishing and liquid chromatography-mass spectrometry analysis. 61
32380350 2020
10
Heptapeptide HP3 acts as a potent inhibitor of experimental imiquimod‑induced murine psoriasis and impedes the trans‑endothelial migration of mononuclear cells. 61
32377714 2020
11
The bidirectional association between type 2 diabetes and psoriasis: Two retrospective cohort studies. 61
32031110 2020
12
Spontaneous resolution of human papillomavirus infection in a patient with psoriasis given secukinumab. 61
32358967 2020
13
Specific IgA and CLA+ T-Cell IL-17 Response to Streptococcus pyogenes in Psoriasis. 61
31972247 2020
14
Apremilast and psoriasis in the real world: A retrospective case series. 61
31604095 2020
15
Excimer laser for psoriasis treatment: A case report and short review. 61
32508993 2020
16
A preliminary prospective non-randomized controlled trial to compare the efficacy of subcutaneous etanercept versus oral methotrexate in moderate-to-severe chronic plaque psoriasis and correlation of response with T helper (th) 1, th2, th17 and T regulatory cytokine patterns. 61
32496226 2020
17
Type D personality is associated with poor quality of life, social performance, and psychological impairment in patients with moderate to severe psoriasis: A cross-sectional study of 130 patients. 61
31857521 2020
18
The risk of myocardial infarction, stroke, and revascularization among patients with psoriasis treated with apremilast compared with biologics and disease-modifying antirheumatic drugs: A cohort study in the US MarketScan database. 61
32222448 2020
19
The vitamin B6-regulated enzymes PYGL and G6PD fuel NADPH oxidases to promote skin inflammation. 61
32126244 2020
20
Rare Loss-of-Function Mutation in SERPINA3 in Generalized Pustular Psoriasis. 61
31945348 2020
21
Histologic comparison of tumor necrosis factor-α inhibitor-induced psoriasis and psoriasis vulgaris. 61
31931086 2020
22
Discovery of triazolo [1,5-a] pyridine derivatives as novel JAK1/2 inhibitors. 61
32527540 2020
23
COVID-19 and biologics for psoriasis: A high-epidemic area experience-Bergamo, Lombardy, Italy. 61
32387660 2020
24
Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biologic treatment and renal transplant recipients in maintenance immunosuppressive treatment. 61
32330632 2020
25
Skin pain and psoriasis. 61
31931087 2020
26
Psoriatic arthritis: A permanent new challenge for dermatologists (Review). 61
32508992 2020
27
Occupational psoriasis after exposure to rockwool. 61
32212156 2020
28
Sudden onset psoriasis causing eruptive seborrheic keratoses. 61
32060898 2020
29
The IL-23/IL-17A axis in spondyloarthritis: therapeutics informing pathogenesis? 61
32412997 2020
30
Expression of pigment epithelium-derived factor in psoriasis, verrucae, squamous cell carcinoma and normal skin: An immunohistochemical study. 61
32372761 2020
31
Real-world trends in biologic, oral systemic, and phototherapy in US patients with psoriasis or psoriatic arthritis. 61
32004649 2020
32
Evaluation of adalimumab biosimilar in treatment of psoriatic arthritis with concomitant moderate to severe chronic plaque psoriasis: An open-labeled, prospective, pilot case series. 61
32087993 2020
33
Integrated serum metabolomics and network pharmacology approach to reveal the potential mechanisms of withanolides from the leaves of Datura metel L. on psoriasis. 61
32302925 2020
34
Use of the Dermatology Life Quality Index work/study domain to estimate overall work productivity loss among patients with psoriasis: an analysis based on real-world data. 61
31736108 2020
35
Differences in Staining for Neutrophil Elastase and its Controlling Inhibitor SLPI Reveal Heterogeneity among Neutrophils in Psoriasis. 61
31945345 2020
36
Clinical and histopathologic features differentiating acute generalized exanthematous pustulosis and pustular psoriasis: A retrospective series. 61
32173359 2020
37
Integrated safety analysis: Frequency of urinary tract infections in patients with psoriasis treated with ixekizumab. 61
32092375 2020
38
Perception of therapeutic inertia by patients with psoriasis in France. 61
32368805 2020
39
Cutaneous syndecan-1 expression before and after phototherapy in psoriasis. 61
32496227 2020
40
Treatment of erythrodermic psoriasis with biologics: A systematic review. 61
32247872 2020
41
Inflammatory marker alteration in response to systemic therapies in psoriasis. 61
32508991 2020
42
Selective targeting of PI3Kδ suppresses human IL-17-producing T cells and innate-like lymphocytes and may be therapeutic for IL-17-mediated diseases. 61
32360069 2020
43
Acute onset of psoriasis in a patient with atopic dermatitis treated with dupilumab. 61
32112580 2020
44
Psoriasis-associated impairment of CCL27/CCR10-derived regulation leads to IL-17A/IL-22-producing skin T cell over-activation. 61
32533971 2020
45
Efficacy and safety of secukinumab in moderate to severe palmoplantar pustular psoriasis over 148 weeks: extension of the 2PRECISE study. 61
32565211 2020
46
2'-fucosyllactose inhibits imiquimod-induced psoriasis in mice by regulating Th17 cell response via the STAT3 signaling pathway. 61
32544868 2020
47
QuantiFERON TB-gold conversion is not uncommon in psoriasis patients under anti-TNF-α: reply from author. 61
32569386 2020
48
Real-life effectiveness and short-term (16-week) tolerance of guselkumab for psoriasis: A Belgian retrospective multicentre study. 61
32535976 2020
49
Association of Skin Psoriasis and Somatic Comorbidity With the Development of Psychiatric Illness in a Nationwide Swedish Study. 61
32492085 2020
50
Ixekizumab improves secondary lesional signs, pain and sexual health in patients with moderate-to-severe genital psoriasis. 61
31919919 2020

Variations for Pustulosis of Palm and Sole

Expression for Pustulosis of Palm and Sole

Search GEO for disease gene expression data for Pustulosis of Palm and Sole.

Pathways for Pustulosis of Palm and Sole

Pathways related to Pustulosis of Palm and Sole according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.59 TNFRSF1B TNF SIGLEC5 PSTPIP1 IL1RN IL1RL2
2
Show member pathways
13.38 TNFRSF1B TNF IL36RN IL1RN IL1RL2 IL17A
3
Show member pathways
12.35 TNF IL36RN IL1RN IL1RL2 CXCL8
4 12.31 TNFRSF1B TNF IL1RN IL17A
5
Show member pathways
12 TNFRSF1B TNF CXCL8 CCR6
6 11.67 TNF CXCL8 CARD14
7 11.6 TNF IL17A CXCL8
8 11.51 TNFRSF1B TNF IL17A CXCL8
9 11.48 TNF IL17A CCR6
10 10.61 TNFRSF1B TNF IL1RN CXCL8
11 10.41 TNF CXCL8 CRP

GO Terms for Pustulosis of Palm and Sole

Biological processes related to Pustulosis of Palm and Sole according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.7 TNFRSF1B TNF IL36RN IL1RN IL17A CXCL8
2 cellular response to lipopolysaccharide GO:0071222 9.56 TNFRSF1B TNF IL36RN CXCL8
3 cytokine-mediated signaling pathway GO:0019221 9.5 TNFRSF1B TNF IL36RN IL1RN IL1RL2 IL17A
4 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.4 TNFRSF1B TNF
5 negative regulation of lipid storage GO:0010888 9.37 TNF CRP
6 positive regulation of interleukin-1 beta biosynthetic process GO:0050725 9.32 TNF IL17A
7 inflammatory response GO:0006954 9.28 TNFRSF1B TNF PSTPIP1 IL36RN IL1RN IL1RL2

Molecular functions related to Pustulosis of Palm and Sole according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 interleukin-1 receptor binding GO:0005149 9.16 IL36RN IL1RN
2 cytokine activity GO:0005125 9.02 TNF IL36RN IL1RN IL17A CXCL8
3 interleukin-1 receptor antagonist activity GO:0005152 8.96 IL36RN IL1RN

Sources for Pustulosis of Palm and Sole

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....